Piper Sandler raised the firm’s price target on Corcept Therapeutics (CORT) to $128 from $78 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $150 from $76 at Truist
- Corcept Therapeutics: Promising Future with Positive Trial Results and Strong Market Position
- Promising Phase 3 Results and Market Potential Drive Buy Rating for Corcept Therapeutics
- Corcept Therapeutics price target raised to $150 from $115 at H.C. Wainwright
- Corcept Therapeutics announces ROSELLA trial meets primary endpoint